FERNANDO
LÓPEZ-RÍOS MORENO
Profesor asociado de Ciencias de la Salud
Hospital Universitario 12 de Octubre
Madrid, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Universitario 12 de Octubre (105)
2024
-
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
The Lancet Regional Health - Europe, Vol. 38
-
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326
-
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma
European Urology Focus
-
Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists
Histopathology, Vol. 84, Núm. 3, pp. 429-439
-
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies
Archives of Pathology and Laboratory Medicine, Vol. 148, Núm. 7, pp. 757-774
-
QIM24-189: Molecular Tumor Boards Excellence. Phase 1-State of the Art in Spain
Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25
-
RET Fusion Testing in Patients With NSCLC: The RETING Study
JTO Clinical and Research Reports, Vol. 5, Núm. 4
-
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049
2023
-
A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma
Translational Lung Cancer Research, Vol. 12, Núm. 7, pp. 1549-1562
-
Caracterización y clasificación molecular del cáncer de pulmón
Revisiones en Cancer, Vol. 37, Núm. 3, pp. 114-120
-
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward
Expert Opinion on Biological Therapy, Vol. 23, Núm. 5, pp. 407-418
-
Pan-TRK Immunohistochemistry to Optimize the Detection of NTRK Fusions: Removing the Hay When Looking for the Needle
Modern Pathology
2022
-
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1335-1354
-
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
BMC Cancer, Vol. 22, Núm. 1
-
Rethinking the role of biomarkers for operable non-small cell lung carcinoma: an effective collaboration with artificial intelligence algorithms
Modern Pathology
2021
-
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
ESMO open, Vol. 6, Núm. 3, pp. 100152
-
Targeted therapy moves to earlier stages of non-small-cell lung cancer: Emerging evidence, controversies and future challenges
Future Oncology, Vol. 17, Núm. 30, pp. 4011-4025
-
Tumor mutational burden assessment in non-small-cell lung cancer samples: Results from the TMB 2 harmonization project comparing three NGS panels
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5
2020
-
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
EBioMedicine, Vol. 53
-
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 167-181